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Abstract
Background: Recent studies have highlighted the potential of cell therapy for atherosclerosis. The aim of this
study was to evaluate the effects of mononuclear cell (MNC) therapy on the development of atherosclerotic lesions
in the apolipoprotein E knockout (apoE KO) mouse.
Methods: We investigated vascular lipid deposition, vascular remodeling, oxidative stress, and endothelial nitric
oxide synthase (eNOS) expression in apoE KO mice treated with spleen MNCs isolated from lacZ transgenic mice
(apoE KO-MNC) for 8 weeks compared to untreated control mice (apoE KO).
Results: Histological analysis of aortas showed a significant reduction in the lipid deposition area in apoE KO-MNC
mice compared to apoE KO mice (0.051 ± 0.004 vs 0.117 ± 0.016 mm
2, respectively, p < 0.01). In addition, vessel
morphometry revealed that MNC therapy prevented the outward (positive) remodeling in apoE KO mice that is
normally observed (apoE KO-MNC: 0.98 ± 0.07 vs apoE KO: 1.37 ± 0.09), using wild-type mice (C57BL/6J) as a
reference. ApoE KO-MNC mice also have reduced production of superoxide anions and increased eNOS expression
compared to apoE KO mice. Finally, immunohistochemistry analysis revealed a homing of endothelial progenitor
cells (EPCs) in the aortas of apoE KO-MNC mice.
Conclusion: MNC therapy attenuates the progression of atherosclerosis in the aortas of apoE KO mice. Our data
provide evidence that the mechanism by which this attenuation occurs includes the homing of EPCs, a decrease in
oxidative stress and an upregulation of eNOS expression.
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Background
Atherosclerosis is a chronic and degenerative disease of
the wall of the large arteries and is a leading cause of
mortality and morbidity [1,2]. Despite progress in the
treatment and repair of this disease, researchers are
continually challenged to develop new successful
approaches. Therapy using stem/progenitor cells has
emerged as an alternative to conventional treatments for
atherosclerosis, as demonstrated by some positive results
in experimental and clinical studies [3,4].
The apolipoprotein E knockout (apoE KO) mouse,
developed two decades ago [5,6], has been used as an
experimental model of atherosclerosis because it sponta-
neously develops hypercholesterolemia and atherosclero-
sis in a reproducible manner, similar to what is
observed in humans. The apoE KO mouse is a particu-
l a r l yu s e f u lm o d e la si to f f e r sau n i q u eo p p o r t u n i t yt o
evaluate the mechanisms involved in the development of
atherosclerosis and new therapies for treatment of this
disease.
One potential therapy for atherosclerosis uses mono-
nuclear cells (MNCs), which contain a subpopulation of
endothelial progenitor cells (EPCs) [7]. However, the
beneficial effects of MNC therapy on atherosclerosis
a r es t i l las u b j e c to fc o n t r o v e r s yi nb o t hh u m a n s[ 8 , 9 ]
and experimental models of atherosclerosis [10,11]. In
this regard, the main objective of the current study was
to evaluate the effects of MNC therapy on vascular
atherosclerotic lesions in apoE KO mice and to elucidate
* Correspondence: evasquez@pq.cnpq.br
1Laboratory of Transgenes and Cardiovascular Control, Dept. Physiological
Sciences, Health Sciences Center, Federal University of Espirito Santo, Vitoria,
ES, Brazil
Full list of author information is available at the end of the article
Porto et al. Lipids in Health and Disease 2011, 10:155
http://www.lipidworld.com/content/10/1/155
© 2011 Porto et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.the mechanisms by which MNC therapy attenuates the
progression of these lesions. We hypothesized that
MNC therapy attenuates the progression of vascular
atherosclerosis through the homing of EPCs, reducing
reactive oxygen species (ROS), and increasing the
expression of endothelial nitric oxide synthase (eNOS).
Materials and methods
Animals
ApoE KO female mice (24-week-old) were randomly
divided into two groups: 1) an apoE KO control group
(n = 8) and 2) an apoE KO group that received MNC
therapy (apoE KO-MNC, n = 8). b-galactosidase (b-gal)
(encoded by the lacZ gene) transgenic mice (12-week-
old) were used as MNC donors. Animals were obtained
from animal facilities at the Federal University of Espir-
ito Santo. Six-month-old apoE KO mice were fed a cho-
lesterol-rich diet (1.25% cholesterol) for 4 months and
were housed separately in temperature-controlled rooms
(22°C) under a 12 h light/dark cycle. All procedures
were conducted in accordance with the institutional
guidelines for animal research and the protocols were
previously approved by the Institutional Ethics Commit-
tee for Use of Animals (CEUA 003/2008).
Isolation of mononuclear cells from spleen
LacZ transgenic mice were euthanized with sodium
thiopental overdose (100 mg/kg, intraperitoneal injec-
tion). The spleens were removed, homogenized, and
mixed with Dulbecco’s Modified Eagle Medium
(DMEM) to nourish the cells. The homogenate was
then loaded onto a histopaque gradient. The layer con-
taining MNCs was removed and resuspended in DMEM
for future intravenous injections.
Transfer of spleen mononuclear cells
For MNC transfusions, 1 × 10
6 MNCs were resus-
pended in 100 μL DMEM and administered by intrave-
nous injections into the tail vein of apoE KO mice over
a period of 2 months (1 injection per week for a total of
8 injections). Uninjected apoE KO mice served as a con-
trol group. We included a control group of a age
matched apoE KO mice that received vehicle-only
(DMEM) injections. To test the preventive effects of
MNC therapy, we also administered MNC transfusions
to younger (16-week-old) apoE KO mice that were fed a
high-cholesterol diet for 2 months prior to the start of
injections.
Measurement of plasma cholesterol levels
A blood sample (200 μL) was collected by intracardiac
puncture of each animal and the plasma total choles-
terol was measured using a commercial colorimetric kit
(Bioclin, Belo Horizonte, Brazil).
Histological analysis of aortic root plaque
At the end of the experiments, each mouse was eutha-
nized with sodium thiopental overdose (100 mg/kg,
intraperitoneal injection) and the left ventricle was per-
fused with 0.1 M phosphate-buffered saline (PBS, pH
7.4) followed by a 4% formaldehyde solution at a pres-
sure of 100 mmHg. The aortic root and a portion of the
ascendant aorta were embedded in OCT compound and
cross-sectioned on a cryostat (Jung CM1800; Leica,
Wetzlar, Germany) at a thickness of 10 μm. For each
animal, aorta cross-sections were mounted on gelatin-
coated slides and stained with Oil-Red-O (Sigma-
Aldrich, St. Louis, MO, USA) to detect neutral lipids.
Morphometry
Images of the aorta were captured with a color video
camera (VKC150, Hitachi, Tokyo, Japan) connected to a
microscope (Olympus AX70, Olympus, Center Valley,
PA, USA) and analyzed using a National Institute of
Health (NIH) Image program. An examiner blinded to
the experimental groups performed the image analysis
to prevent any bias is the interpretation of the results.
Using a 4 × objective, the vessel cross-sectional area
(VCSA) and the lumen cross-sectional area were calcu-
lated. The vascular remodeling ratio was obtained by
dividing each animal’sV CSA by the average VCSA of
wild-type C57BL/6J (C57) mice and each sample was
scored for absence of remodeling (0.95-1.05), inward
remodeling (< 0.95), or outward remodeling (> 1.05).
Localization of donor MNCs
The remaining whole aorta was opened lengthwise and
stained en face for donor MNC localization. Aortic sam-
ples were incubated for 12 h at 37°C in freshly prepared
b-gal staining solution (pH 4.0) containing 2.4 mM 5-
bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal,
Sigma Aldrich), 4.7 mmol/L potassium ferrocyanide, 4.9
mmol/L potassium ferricyanide, 150 mmol/L NaCl, 1
mmol/L MgCl2 and 40 mmol/L citric acid.
Detection of superoxide production
Unfixed frozen sections of aorta were incubated in 2
μmol dihydroethidium (DHE) modified Kreb’ss o l u t i o n
containing 20 mmol of HEPES for 30 min in a light-
protected chamber at 37°C.
Immunohistochemistry
Cross-sections (10 μm) were cut on a cryostat and
placed on gelatin-coated slides. Sections were air-dried
and then slides were fixed for 20 minutes in acetone at
-20°C. Slides were incubated with the following primary
antibodies overnight: eNOS, 1:50 (BD Pharmingen, San
Diego, CA, USA); vascular endothelial grown factor
receptor (Flk-1), 1:50 (Abcam, Cambridge, MA, USA);
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pore, Billerica, MA, USA). A Vectastain ABC Elit kit
was used for detection, with DAB or NovaRED staining
(Vector Laboratories, Burlingame, CA, USA).
Statistical Analysis
Data are presented as the mean ± SEM. Statistical analy-
sis was performed with Student’s t-test for independent
samples. One-way analysis of variance (ANOVA), fol-
lowed by the Tukey post hoc test for multiple compari-
sons, was used when appropriate. Statistical significance
was set at p < 0.05.
Results
Plasma total cholesterol levels of 24-week-old animals
that were fed a high-cholesterol diet for 16 weeks was
similar between apoE KO control mice and apoE KO
mice that received MNC therapy for 8 weeks (1176 ±
213 vs. 1241 ± 167 mg/dL; p > 0.05).
Figure 1 shows the effect of MNC therapy on vessel
lipid deposition. As shown by the histological analysis of
a typical aortic root cross-section, apoE KO-MNC mice
demonstrated marked reduction of the atherosclerotic
lesion. A large lipid deposition area was observed in the
aorta roots of 24-week-old apoE KO control and vehi-
cle-only mice (0.117 ± 0.016 mm
2 and 0.109 ± 0.012
mm
2, respectively). In contrast, the lipid deposition area
was significantly reduced in approximately 45% (p <
0.01) of age-matched apoE KO-MNC mice (bar graph,
Figure 1). This value of apoE KO-MNC was statistically
similar to that observed in 16-week-old apoE KO mice
(0.051 ± 0.004 vs. 0.049 ± 0.005 mm
2, respectively), indi-
cating that MNCs have atheroprotective properties.
Figure 2 summarizes data obtained from measure-
ments of the aorta cross-sectional area and vascular
remodeling in apoE KO and apoE KO-MNC mice, using
wild-type C57 animals as reference values. The vessel
lumen area was statistically similar in all groups ana-
lyzed. However, the vessel wall area was significantly
increased in apoE KO mice (0.79 ± 0.05 mm
2)c o m -
pared to C57 mice (0.37 ± 0.05 mm
2,p<0 . 0 1 ) .T h i s
increase was subsequently normalized by MNC therapy
(apoE KO-MNC: 0.39 ± 0.04 mm
2, p < 0.01). Consistent
with this finding, the positive (> 1.05) vascular remodel-
ing observed in apoE KO mice was prevented by MNC
therapy (ratios of 1.37 ± 0.09 in apoE KO vs. 0.98 ± 0.07
in apoE KO-MNC).
Figure 3 shows typical en face aortas from apoE KO
and apoE KO-MNC mice that were stained with b-gal
to identify donor-derived MNCs. All apoE KO animals
that received MNC therapy from lacZ transgenic mice
expressed b-gal staining in the aorta roots when com-
pared with untreated and vehicle-only mice (data not
shown), which lacked any vessel b-gal staining.
To investigate the mechanisms by which MNC ther-
apy reduced atherosclerosis, we evaluated superoxide
(O2
·-) production, eNOS production, and homing of
endothelial progenitor cells. As illustrated in the micro-
photographs in Figure 4 (top panel), a dihydroethidium
oxidative assay revealed intense ethidium fluorescence
Figure 1 Effect of MNC therapy on lipid deposition in aortas of
apoE KO mice. Top panel are typical photomicrographs of aorta
root cross-sections comparing an apoE KO-MNC aorta to an apoE
KO control aorta. (Oil-Red-O stain, original magnification × 4. Bar:
100 μm). Bar graph shows the average lipid deposition area
comparing apoE KO-MNC to apoE KO group. Values are means ±
SEM. **p < 0.01 compared to apoE KO (Student’s t test).
Figure 2 Effect of MNC therapy on vessel and lumen cross-
sectional areas. Values are means ± SEM. **p < 0.01 compared to
wild-type C57 vessel area;
##p < 0.01 compared to the apoE KO
vessel area (one-way ANOVA). Numbers above the bars indicate the
remodeling ratio using the C57 group as reference value and (+)
indicates a positive (outward) remodeling.
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mouse. On average, the aortas from apoE KO-MNC
mice exhibited approximately 60% less ethidium fluores-
cence than untreated apoE KO mice (Figure 4, bottom
panel). In addition, qualitative immunohistochemistry in
aortas from apoE KO-MNC revealed increased expres-
sion of eNOS compared to untreated apoE KO mice
(Figure 5). Homing of endothelial progenitor cells was
confirmed by immunohistochemistry detection of Flk-1
and CD133, markers of endothelial progenitor cells,
which showed a marked increase in Flk-1 and CD133
staining in the aorta endothelium of apoE KO-MNC
mice compared to untreated apoE KO mice (illustrations
in Figure 6).
Discussion
In the present study we observed that 8 weeks of MNC
therapy resulted in the attenuation of atherosclerotic
lesions in aortas from apoE KO mice through the hom-
ing of EPCs, a reduction in the production of superoxide
anions and an increase in eNOS expression.
Stem/progenitor cells, a subpopulation of MNCs, have
unique characteristics that make them ideal for thera-
peutic purposes. They are undifferentiated, unspecia-
lized, and can divide symmetrically and asymmetrically
for long periods [12-14]. In the present study we
observed that MNCs have atheroprotective properties in
Figure 3 Typical photograph of an aorta root stained en face
showing b-gal-positive cells (blue) derived from lacZ mice in
the apoE KO-MNC mouse, compared to the lack of staining in
the apoE KO mouse.
Figure 4 Effect of MNC therapy on superoxide anion
production in the aorta of apoE KO mice. Top panel contains
representative cross-sections stained with dihydroethidium (DHE)
showing a bright ethidium fluorescence (red) in the apoE KO
mouse compared to the apoE KO-MNC mouse (original
magnification × 20. Bar: 50 μm). Bar graph shows average DHE
fluorescence (AU: arbitrary units) comparing apoE KO to apoE KO-
MNC mice. Values are means ± SEM. *p < 0.05 compared to apoE
KO, Student’s t test).
Figure 5 Effect of MNC therapy on eNOS protein production in
aortas of apoE KO mice. Representative microphotographs reveal
a positive immunoreaction (brown precipitates, indicated by arrow)
for eNOS in the endothelium of the apoE KO-MNC mouse
compared to the apoE KO mouse. (DAB stain, original magnification
× 20. Bar: 50 μm).
Figure 6 Homing of endothelial progenitor cells after MNC
therapy in apoE KO mice. Photomicrographs are typical aorta
cross-sections stained for the markers Flk-1 (vascular endothelial
growth factor receptor) and CD133 (hematopoietic stem cell
antigen) showing an intense immune reaction (red precipitate) in
MNC-treated animals. (original magnification × 20. Bar: 50 μm).
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under conditions of high total cholesterol in the plasma.
The development of atherosclerosis was accelerated by a
high-cholesterol diet; however, continuous treatment
with MNCs derived from young lacZ transgenic mice
caused a marked attenuation of the atherosclerotic
lesion, without affecting the high total cholesterol levels
in the plasma. This finding is in agreement with other
studies in aortas [10,15] and carotid arteries [16] from
murine models of atherosclerosis but conflicts with one
study which found no significant effects from MNC
therapy on atherosclerosis [17] and two studies which
observed opposite results to ours [11,18]. This discre-
pancy could be due to the different methods used in
these studies. For example, the study that found that
there was no benefit from MNC therapy [17] treated the
animals with fewer injections of MNCs (1 to 3 injections
at similar concentrations) than did we and others
[10,15] who observed a beneficial effect (6 to 8 injec-
tions). Other variable factors include the animal’sa g e
and gender.
The vascular remodeling of large arteries is considered
an adaptive structural change that occurs in response to
a variety of conditions, including atherosclerosis [19,20].
Our finding of a positive (outward) remodeling in aortas
from apoE KO control mice corroborates this adaptive
morphological change and is in agreement with previous
studies [21-23]. A novel finding of this study revealed
that animals that received MNC therapy (apoE KO-
MNC mice) did not show vascular positive remodeling,
most likely as a direct consequence of marked attenua-
tion of the atherosclerotic process.
The X-gal en face analysis of aortas from apoE KO
mice revealed the presence of donor MNCs (from a
lacZ mouse) in atherosclerotic areas, indicating that the
therapeutic effect of MNCs is at the level of the arterial
wall, as has been described by others [10,24,25]. We
then investigated the possible mechanisms by which
MNCs could locally mediate the attenuation of athero-
sclerosis in apoE KO mice.
It is known that the number of circulating EPCs is
inversely proportional to the risk of cardiovascular dis-
eases [26], suggesting that increasing the number of cir-
culating EPCs could be a powerful therapy in the
treatment of atherosclerosis [10,27]. Based on what has
been done in other studies [28], we used the spleen as a
source of EPCs, which are contained within the mono-
nuclear fraction. Our hypothesis that EPCs derived from
the MNC fraction are involved in the anti-atherogenic
response is based on our discovery of vascular homing
of EPCs and the presence of markers Flk-1 and CD133
in aortas from apoE KO mice treated with MNCs
[29,30]. As shown in Figure 6, aorta cross-sections from
apoE KO-MNC mice showed intense expression of EPC
markers. This indicates that in the presence of EPCs,
the vessel wall is capable of accelerating the re-endothe-
lialization and inhibition of neointimal formation. This
mechanism of action by EPCs has also been demon-
strated by others [31].
Clinical and experimental studies of atherosclerosis,
including those using the apoE KO mouse model, sup-
port the concept that overabundance of ROS and/or a
decline in antioxidant ability plays a causal role in ather-
osclerosis [32,33]. Moreover, the integrity of eNOS/NO
production in the vasculature is critical for normal vas-
cular function [34]. The effects of cell therapy on ROS
production have not previously been studied in experi-
mental atherosclerosis. To address this, in the present
study we tested the hypothesis that the beneficial effects
of MNC includes a reduction in oxidative stress. We
found that MNC therapy in apoE KO mice resulted in a
marked decrease in O2
·- production and a concomitant
upregulation of eNOS in the aorta, supporting the idea
that another important mechanism by which MNC ther-
apy attenuates the progression of atherosclerosis is by
relieving oxidative stress. Thus, we speculate that the
increased number of circulating EPCs provided by MNC
therapy upregulated the NO pathway. This finding is
consistent with other studies that observed similar
results in a model of experimental diabetes [35].
I nc o n c l u s i o n ,w eh a v es h o w nt h a tM N Ct h e r a p y
attenuates atherosclerotic lesions in aortas from apoE
KO mice. Our data provide evidence that the mechan-
isms by which MNC therapy is atheroprotective include
homing of EPCs, reducing O2
·- production and upregu-
lating eNOS expression. Although further studies are
needed to reveal additional mechanisms underlying the
atherosclerotic process in this murine model, the pre-
sent data provide important evidence on the beneficial
effect of cell therapy on atherosclerosis.
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